# Claiborne R. Rankin

> Claiborne R. Rankin is a Series A investor at North Coast Ventures backing Medical and Health Care. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [North Coast Ventures](https://shizune.co/investors/profile/north-coast-angel-fund)
- Total investments: 6
- Last investment: Apr 2014
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/claibornerankin

Claiborne R. Rankin is a Series A investor at North Coast Ventures focused on Medical and Health Care. Clay is the Managing Member of North Coast Angel Fund, a venture capital fund he co-founded in 2006 to support early-stage, Ohio-based technology companies.Previously, Clay was a founding partner of Sycamore Partners, LLC, a company that focused on providing fund-raising, Board of Directors, and consulting support to pre-seed and seed-stagecompanies.His previous experience spans leadership positions at several organizations, including his work as President and COO of Bruning Paint Company and Vice President of Corporate Development and CFO of Laurel Industries, Inc.Clay serves on the Boards of Directors of a subsidiary of a NYSE-traded company and several start-up companies, including LogicBay Corporation and NCAF portfolio companies Neuros Medical, OnShift, and SironRX Therapeutics (Chair).He holds a bachelor’s degree from Yale University and an MBA from Harvard Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 33% |
| Health Care | 2 | 33% |
| Therapeutics | 2 | 33% |
| SaaS | 1 | 17% |
| Hospital | 1 | 17% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 50% |
| Funding Round | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neuros Medical | Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. | $4M |  | Apr 01, 2014 |  |
| Neuros Medical | Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. | $3.5M |  | Jul 18, 2012 |  |
| Neuros Medical | Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. |  | Series A | Nov 11, 2011 |  |
| SironRX Therapeutics | SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote dermal wound repair and reduce scarring. Our lead product is a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is key molecule responsible for activating natural repair processes aftertissue injury through prevention of cell death and recruitment of stem cells to the damaged organ. Studies from several laboratories suggest the therapeutic potential of SDF-1 for treatment of a range of wounds such as post-surgical incisions, chronic diabetic ulcers and burns. Development of a cost-effective interactive wound therapy that can be topically administered at the site-of-injury or in chronic wound care settings with the potential to significantly improve function of the damaged tissue will have a major impact on the multi-billion dollar advanced wound management market. | $3.4M | Series A | Aug 16, 2011 |  |
| OnShift | OnShift delivers cloud-based human capital management software and proactive services to solve everyday workforce challenges in healthcare. Our suite of products for hiring, scheduling and employee engagement drives quality care, lower costs and higher performance by empowering providers to staff consistently and efficiently. Intuitive design,predictive analytics and customer success management are why thousands of post-acute care and senior living organizations rely on OnShift. | $2.3M | Series A | Dec 06, 2010 |  |
| Neuros Medical | Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. | $375K |  | Mar 01, 2009 |  |

6 of 6 investments shown.

## Co-investors
- [JumpStart Inc.](https://shizune.co/investors/profile/jumpstartinc) — VC Fund, 3 deals together
- [Early Stage Partners](https://shizune.co/investors/profile/early-stage-partners) — VC Fund, 2 deals together
- [Glengary Ventures](https://shizune.co/investors/profile/glengary-ventures) — VC Fund, 2 deals together
- [Ohio TechAngels Fund](https://shizune.co/investors/profile/ohio-techangels-fund) — VC Fund, 2 deals together
- [BlueTree Allied Angels](https://shizune.co/investors/profile/bluetree-allied-angels) — VC Fund, 1 deal together
- [Boston Scientific](https://shizune.co/investors/profile/boston-scientific) — VC Fund, 1 deal together

## About North Coast Ventures

VC Fund · Cleveland, United States

North Coast Ventures (formerly North Coast Angel Fund) is comprised of four contributed capital funds with a focus on early-stage technology investments. Our membership consists of a number of Ohio's leading investors, entrepreneurs, and business leaders who are dedicated to accelerating early-stage ventures.North Coast Ventures members playan active role by generating deal flow, serving on due diligence teams, working with portfolio companies, or serving on the Investment Screening and Executive Committees. Through this involvement, our goal is to provide a supportive environment for our portfolio companies and ultimately enhance the performance of our Fund.Northeast Ohio has a long tradition of active and successful angel investing, but until recently, the success of this crucial form of funding has hinged on the efforts of a relatively small number of individual investors. As the region’s first professionally managed angel fund, North Coast Angel Fund works to improve the early-stage funding environment for both entrepreneurs and investors.

5 contacts available at North Coast Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Claiborne R. Rankin | Managing Member | https://shizune.co/investors/profile/claiborne-r-rankin |
| Daniel Luketic | Director | https://shizune.co/investors/profile/daniel-luketic |
| Todd Federman | Executive Director | https://shizune.co/investors/profile/todd-federman |
| Ben Sheridan | Member | https://shizune.co/investors/profile/ben-sheridan |
| Ben Sheridan | Member | https://shizune.co/investors/profile/ben-sheridan-772f |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Claiborne R. Rankin invest in?

Claiborne R. Rankin invests primarily in Medical, Health Care and Therapeutics startups, most often at Series A and Funding Round stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Claiborne R. Rankin last invest?

The most recent investment recorded for Claiborne R. Rankin closed in Apr 2014. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co